EOLS - CIK 0001570562
Evolus, Inc. trades as EOLS. In its fiscal 2025 annual report the company posted revenue of $297.18M, up 11.6% from the prior year and net income of -$51.64M. This page tracks Evolus, Inc. through 543 SEC filings, with financial statements and metrics updated as new reports are filed.
Net profit margin expanded from -257.8% to -17.4% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Quarterly report | 10-Q | 2026-05-04 |
| Major company event | 8-K | 2026-05-04 |
| Proxy materials | DEFA14A | 2026-04-29 |
| Proxy statement | DEF 14A | 2026-04-29 |
| Annual report to shareholders | ARS | 2026-04-29 |
| SCHEDULE 13G/A | - | 2026-03-26 |
| Insider trade | 4 | 2026-03-20 |
| Insider trade | 4 | 2026-03-20 |
The largest companies sharing Evolus, Inc.'s SEC industry classification (pharmaceutical preparations).
Evolus, Inc. reported revenue of $297.18M for fiscal year 2025, an increase of 11.6% year over year.
In its latest fiscal year Evolus, Inc. reported a net loss of $51.64M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.